• 

  Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir

  Business | May 13, 2020 11:43 IST

  Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19.

• 

  Cipla announces closure of USFDA inspection at Patalganga facility

  Business | January 20, 2020 16:25 IST

   Cipla on Monday announced the closure of inspection by the US health regulator at its Patalganga manufacturing facility in Maharashtra.

• 

  Lifting ban on FDC drugs against patients' safety: Centre

  India | March 21, 2016 22:15 IST

  The government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety"

• 

  Cipla completes acquisition of two US firms for nearly Rs 3,650 crore

  February 18, 2016 17:30 IST

  New Delhi: Pharmaceutical firm Cipla on Thursday announced that its UK arm, Cipla (EU) has closed the $550 million (approximately Rs 3,650 crore) deal to acquire two US-based firms, InvaGen Pharmaceuticals and Exelan Pharmaceuticals.The acquisition

• 

  Cipla to launch generic Hepatitis C drug 'Hepcvir' in India

  March 25, 2015 16:27 IST

  Drug major Cipla today announced the launch of generic drug Sofosbuvir for treating chronic Hepatitis C under the brand name 'Hepcvir', in India."Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year

• 

  Cipla promoters firm buys out minority investors in Okasa

  January 15, 2015 11:37 IST

  Mumbai: Hamsons, a firm owned by the promoter family of pharmaceuticals major Cipla, has bought out the remaining 21 per cent equity owned by minority shareholders in Satara-based Okasa Pharma for an undisclosed amount, completing

• 

  Cipla shares fall almost 3% post Q2 results

  November 14, 2014 15:00 IST

  Mumbai: Shares of drug major Cipla fell almost three per cent today after the company's September quarter results came in below market expectations.Cipla's scrip lost 2.93 per cent to Rs 605.85 at the BSE. At

• 

  Cipla asks govt to revoke Novartis patents on respiratory drug

  October 30, 2014 15:46 IST

  New Delhi: Generic drugmaker Cipla has requested the NDA government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez.The move would help the company to boost its access in the

• 

  Cipla signs pact with Teva for selling drugs in South Africa

  October 09, 2014 14:09 IST

  New Delhi: Drugmaker Cipla today announced a collaboration with Israel's Teva Pharmaceuticals for sales and distribution of the latter's drugs in South Africa.The agreement is between Medpro Pharmaceuticals, a subsidiary of Cipla Medpro and Teva

• 

  Cipla continues its overseas expansion, inks pact to acquire 51% stake in Yemeni firm

  June 30, 2014 21:02 IST

  New Delhi: Continuing its overseas acquisitions, pharma major Cipla has inked a pact with a Yemeni firm to acquire its majority stake for USD 21 million (over Rs 125 crore). The company has signed a

• 

  Cipla to pick 14.6% stake in Chase Pharmaceuticals for $1.5 mn

  May 12, 2014 14:51 IST

  New Delhi: Drug firm Cipla Ltd on Monday said it will acquire 14.6 percent stake in US-based Chase Pharmaceuticals Corporation Inc for USD 1.5 million.The investment will be done through Cipla's wholly owned subsidiary Cipla

Advertisement
• 

  India can be leader in supplying medicines, says Cipla Chairman YK Hamied

  May 04, 2014 16:37 IST

  New Delhi: Cipla Chairman Yousuf K Hamied has said India can be a global leader in supplying affordable and high quality medicines to the world, especially to the underdeveloped countries where such medicines do not

• 

  India can be leader in supplying medicines: Cipla chairman

  May 03, 2014 20:19 IST

  New Delhi: India can be a global leader in supplying affordable and high quality medicines to the world, and especially to the underdeveloped countries where such medicines do not reach the poor because of their

• 

  Drugs pricing row: HC extends relief to Cipla till Aug 27

  July 31, 2013 6:49 IST

  New Delhi, Jul 31:  Delhi High Court yesterday extended the operation of its earlier order asking the Centre not to take coercive steps against pharma major Cipla Ltd which was told to replace stocks in

• 

  LIC sells Cipla shares for Rs 665 crore; cuts stake to 6.21%

  January 13, 2013 7:10 IST

  New Delhi, Jan 13: Drug major Cipla has said state-run Life Insurance Corporation has sold 2.12 per cent stake in it through open market transactions for Rs 665.39 crore.The insurer has reduced its stake to

• 

  Cipla slashes cancer drug prices by up to 64%

  November 08, 2012 18:49 IST

  New Delhi, Nov 8: Giving some relief to cancer patients, pharma major Cipla today slashed prices of its three generic cancer drugs by up to 64 per cent.Drugs under the brand names Erlocip, Docetax and

• 

  Cipla Q2 net up 62% at Rs 500 cr

  November 05, 2012 17:53 IST

  New Delhi, Nov 5: Drug firm Cipla Ltd on Monday said its consolidated net profit rose by 61.83 per cent to Rs 500.01 crore for the second quarter ended September 30, 2012, due to robust

• 

  Cipla's anti-malaria drug receives WHO pre-qualification

  October 04, 2012 19:04 IST

  New Delhi, Oct 4: Drug firm Cipla on Thursday said an anti-malarial drug developed by Drugs for Neglected Diseases initiative (DNDi) has received pre-qualification from the World Health Organisation (WHO).The Mumbai-headquartered firm is manufacturing the

• 

  Cipla Promoters Not Selling Out

  August 25, 2011 20:47 IST

  Mumbai, Aug 25: Pharma major Cipla today said it is expecting to scale up its revenue by over six times to Rs 15,000-20,000 crore by 2020 and assured shareholders the promoters have no plan to